Prot #NU MSK20C04: The PROTECT Study: A Phase II, Open-Label Trial of PROphylactic Skin Toxicity ThErapy with Clindamycin and Triamcinolone in Glioblastoma Patients Treated with Tumor Treating Fields

Project: Research project

Project Details

StatusActive
Effective start/end date4/20/214/20/24

Funding

  • Memorial Sloan-Kettering Cancer Center (Prot #NU MSK20C04)
  • Novocure GmbH (Prot #NU MSK20C04)